mRNA Revolution: a new generation of medicine - updated for 2025
The UK’s life sciences sector has always been defined by its pioneering spirit. Today, that spirit is driving a revolution in medicine, with mRNA technology at its core. This report, mRNA Revolution: A new generation of medicine, serves as a testament to the remarkable progress we have made in the UK, moving from a field of great promise to a strategic national asset.
At the BIA, we have a unique vantage point on the collaborative ecosystem that has made this possible. The past year has seen commitments from global leaders like Moderna and BioNTech evolve into tangible facilities, clinical trials, and investments that are already transforming our landscape. This is a clear signal that the world views the UK as a premier destination for mRNA innovation.
Our shared success is built on a foundation of proactive policy and strategic partnerships. The government’s investment in crucial infrastructure like the UK RNA Biofoundry and the industry-wide focus on closing the skills gap through initiatives like the ATAC Apprenticeship Programme demonstrate our collective commitment to a resilient, end-to-end UK supply chain, which allows SMEs to grow and scale in the UK.
This report showcases our ability to attract investment, innovate, and translate cutting-edge science into patient benefits. I encourage our members to engage with the BIA’s mRNA community and to continue this vital work. By doing so, we will not only strengthen the UK’s position but also accelerate the delivery of transformative medicines for the future.
In this updated version of our mRNA Revolution report, we dive into this pivotal moment for the UK’s life sciences sector, providing new insights into the strategic areas that are shaping its future. We have significantly expanded our coverage on the evolving regulatory landscape, the critical role of apprenticeships and skills development, and the changing dynamics of investment to reflect the UK’s proactive approach to cementing its position as a global leader in mRNA innovation.
Discover how the evolving regulatory landscape, targeted investment, and exceptional talent are transforming the UK into a global hub for mRNA innovation.